AQST - アクエスティブ・セラピュ―ティクス (Aquestive Therapeutics Inc.) アクエスティブ・セラピュ―ティクス

 AQSTのチャート


 AQSTの企業情報

symbol AQST
会社名 Aquestive Therapeutics Inc (アクエスティブ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Aquestive Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant Sympazan and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108 and AQST-305 for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs which includes Suboxone and APL-130277 for the treatment of opioid dependence and Parkinson’s disease.   アクエスティブ・セラピュ―ティクスは米国の特殊医薬品企業。主に満たされていない医療ニ―ズに焦点を当て、製品の特定や開発、商業化に従事する。同社の「PharmFilm」は既存の処方薬を直接血流に送達するプラットフォ―ム医薬製剤。医薬品フィルム、個別使用フィルム、患者・医師・介護用のフィルムなどを製造する。本社所在地はニュ―ジャ―ジ―州ウォ―レン。   Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.
本社所在地 30 Technology Drive Warren NJ 07059 USA
代表者氏名
代表者役職名
電話番号 +1 908-941-1900
設立年月日 37987
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 195人
url www.aquestive.com
nasdaq_url https://www.nasdaq.com/symbol/aqst
adr_tso
EBITDA EBITDA(百万ドル) -20.56200
終値(lastsale) 15.775
時価総額(marketcap) 393203343.425
時価総額 時価総額(百万ドル) 369.13940
売上高 売上高(百万ドル) 76.67900
企業価値(EV) 企業価値(EV)(百万ドル) 404.93140
当期純利益 当期純利益(百万ドル) -35.23500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aquestive Therapeutics Inc revenues increased 35% to $37.3M. Net loss applicable to common stockholders increased from $8.6M to $32.4M. Revenues reflect United States segment increase of 46% to $23.2M Malaysia segment increase of 22% to $33K. Higher net loss reflects Selling General and administrative increase from $10.6M to $41.2M (expense) Research_Development increase of 18% to $12.9M (expense).

 AQSTのテクニカル分析


 AQSTのニュース

   Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Forecast For 2021: Bullish Signs Point To $28.00 Per Share  2021/12/06 14:30:00 Marketing Sentinel
In the last trading session, 1.14 million Aquestive Therapeutics Inc. (NASDAQ:AQST) shares changed hands as the companys beta touched 3.47. With the companys per share price at $4.84 changed hands at -$0.54 or -10.04% during last session, the market valuation stood at $216.11M. AQSTs last price was a discount, traded about -66.53% off its 52-week Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Forecast For 2021: Bullish Signs Point To $28.00 Per Share Read More »
   Squarepoint Ops LLC Makes New $79,000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)  2021/11/27 10:08:44 Dakota Financial News
Squarepoint Ops LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,824 shares of the companys stock, valued at approximately $79,000. Squarepoint Ops LLC owned approximately 0.05% of Aquestive []
   Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth?  2021/11/25 12:30:00 Marketing Sentinel
During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)s traded shares were 0.6 million, with the beta value of the company hitting 3.51. At the end of the trading day, the stocks price was $6.24, reflecting an intraday gain of 4.17% or $0.25. The 52-week high for the AQST share is $8.06, that puts it down Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth? Read More »
   Aquestive Therapeutics, Inc. (NASDAQ:AQST) Expected to Post Earnings of -$0.37 Per Share  2021/11/24 17:10:42 Transcript Daily
Brokerages expect that Aquestive Therapeutics, Inc. (NASDAQ:AQST) will report earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aquestive Therapeutics earnings, with estimates ranging from ($0.42) to ($0.32). Aquestive Therapeutics posted earnings per share of ($0.60) during the same quarter last year, which []
   Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Increase in Short Interest  2021/11/23 06:24:42 Transcript Daily
Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large increase in short interest in October. As of October 29th, there was short interest totalling 1,480,000 shares, an increase of 22.3% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 495,300 shares, the days-to-cover ratio is currently 3.0 days. Hedge funds have […]
   Squarepoint Ops LLC Makes New $79,000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)  2021/11/27 10:08:44 Dakota Financial News
Squarepoint Ops LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,824 shares of the companys stock, valued at approximately $79,000. Squarepoint Ops LLC owned approximately 0.05% of Aquestive []
   Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth?  2021/11/25 12:30:00 Marketing Sentinel
During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)s traded shares were 0.6 million, with the beta value of the company hitting 3.51. At the end of the trading day, the stocks price was $6.24, reflecting an intraday gain of 4.17% or $0.25. The 52-week high for the AQST share is $8.06, that puts it down Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth? Read More »
   Aquestive Therapeutics, Inc. (NASDAQ:AQST) Expected to Post Earnings of -$0.37 Per Share  2021/11/24 17:10:42 Transcript Daily
Brokerages expect that Aquestive Therapeutics, Inc. (NASDAQ:AQST) will report earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aquestive Therapeutics earnings, with estimates ranging from ($0.42) to ($0.32). Aquestive Therapeutics posted earnings per share of ($0.60) during the same quarter last year, which []
   Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Increase in Short Interest  2021/11/23 06:24:42 Transcript Daily
Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large increase in short interest in October. As of October 29th, there was short interest totalling 1,480,000 shares, an increase of 22.3% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 495,300 shares, the days-to-cover ratio is currently 3.0 days. Hedge funds have […]
   Wedbush Equities Analysts Decrease Earnings Estimates for Aquestive Therapeutics, Inc. (NASDAQ:AQST)  2021/11/06 09:50:41 Dakota Financial News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Equities researchers at Wedbush lowered their FY2023 earnings estimates for shares of Aquestive Therapeutics in a report issued on Wednesday, November 3rd. Wedbush analyst L. Moussatos now forecasts that the company will earn $1.04 per share for the year, down from their prior forecast of $1.10. Wedbush also issued estimates []
   Analysts Offer Predictions for Aquestive Therapeutics, Inc.s FY2023 Earnings (NASDAQ:AQST)  2021/11/05 13:28:43 Transcript Daily
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock analysts at Wedbush decreased their FY2023 EPS estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Wednesday, November 3rd. Wedbush analyst L. Moussatos now expects that the company will post earnings of $1.04 per share for the year, down from their previous []
   81,765 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Purchased by PDT Partners LLC  2021/11/04 12:10:41 Transcript Daily
PDT Partners LLC acquired a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 81,765 shares of the companys stock, valued at approximately $325,000. A number of other large investors have also recently made changes to their positions in the business. Financial Advocates Investment Management boosted []
   Aquestive Therapeutics Inc. (NASDAQ: AQST) Continues To Thrive In 2021, As Its Stock Is Up 10.28% Year-To-Date  2021/11/04 11:00:00 Marketing Sentinel
During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)s traded shares were 1.38 million. At the end of the trading day, the stocks price was $5.90, reflecting an intraday gain of 10.07% or $0.54. The 52-week high for the AQST share is $8.06, that puts it down -36.61 from that peak though still a striking 47.46% Aquestive Therapeutics Inc. (NASDAQ: AQST) Continues To Thrive In 2021, As Its Stock Is Up 10.28% Year-To-Date Read More »
   Aquestive Therapeutics EPS beats by $0.06, beats on revenue  2021/11/02 21:17:51 Seeking Alpha
   Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance  2021/11/02 20:30:00 Intrado Digital Media
WARREN, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent developments in its business.

 関連キーワード  (医薬品 米国株 アクエスティブ・セラピュ―ティクス AQST Aquestive Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)